Yoeri Bemelmans

Chapter 7 108 Table 1. Continued. Author Year Type of arthroplasty Country Setting Design of study Richter et al. 35 2017 UKA USA Tertiary care hospital and ASC Retrospective observational study Schoifet et al. 52 2011 TKA USA Secondary care hospital Quasi experimental design (prospective treatment arm and retrospective control arm) Schotanus et al. 36 2017 TKA and UKA NL Secondary care hospital Retrospective observational study Schotanus et al. 37 2017 TKA NL Secondary care hospital Prospective observational study Springer et al. 38 2017 THA and TKA USA Hip and knee center Retrospective observational study Weiser et al. 53 2018 THA USA Tertiary care hospital Retrospective observational study THA, total hip arthroplasty; RHA, resurfacing hip arthroplasty; TKA, total knee arthroplasty; UKA, unicompartmental knee arthroplasty; USA, United States of America; FR, France; DK, Denmark; NL, Netherlands; CA, Canada; HS-PDPR, Humana subset PearlDiver Patient Record; ASC, ambulatory surgical center; ACS-NSQIP, Amercian College of Surgeons National Surgical Quality Improvement Complications ((S)AEs) Overall complication rates were described in 33 studies (OS= 19; SOS= 14) [2,3,4,5,6, 19,20,21,22,23,24,25, 28, 29, 31, 32, 34, 35, 38,39,40,41,42,43,44,45,46,47,48,49,50,51,52] . No significant differences were found for overall complication rates in OJA pathways (OS, P=0.24; SOS, P=0.71) compared to inpatient pathways (Fig. 4). Adverse events (AEs) were described in 27 studies (OS=17, SOS=10) [2,3,4,5,6, 19, 21, 22, 24, 25, 28, 29, 31, 32, 34, 35, 38,39,40,41, 44,45,46,47,48,49, 52]. For OS studies, only THAs showed statistically significant fewer AEs in outpatient pathways [OR=0.55 (0.41– 0.74); I2=0%] compared to inpatient pathways (Fig. 5). For SOS studies, no statistically significant differences (by types of arthroplasty) were found for AEs between the two pathways.